1 completed, 1 recruiting, 1 unknown. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow BEBT-908: new trials by email Literature Review of BEBT-908 trials Research Report on BEBT-908
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Ifupinostat Hydrochloride - B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 15 | 2026-09-01 | 2026-10-02 |
| Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma BEBT-908 for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Unknown | BeBetter Med Inc | 75 | 2023-12-01 | 2023-12-11 |
| Study of BEBT-908 in Subjects With Advanced Hematological Tumors BEBT-908 for injection - Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma | Phase 1 | Completed | BeBetter Med Inc | 32 | 2016-03-02 | 2023-10-13 |
Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Recurrence (1)
BeBetter Med Inc (2) · The First Affiliated Hospital of Soochow University (1)
China (3)
Hui Zhou, Phd (1) · Yuankai Shi, Phd (1)